Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Type 1-diabetes forlængelsesundersøgelse (T1DES)

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).

This observational study will:

  • follow participants to determine how long they continue to produce insulin, and
  • will also assess how changes in the immune system over time relate to the ability to produce insulin.

This information could help design better therapies for type 1 diabetes in the future.

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:

  • Overall health assessments
  • Blood and urine collections
  • Mixed meal tolerance test (MMTTs) for certain participants, per protocol.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

111

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • UCSF School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Stephen Gitelman, MD
      • Stanford, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford University
        • Kontakt:
        • Ledende efterforsker:
          • Darrell Wilson, MD
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado School of Medicine: Barbara Davis Center for Diabetes
        • Ledende efterforsker:
          • Peter Gottlieb, MD
        • Kontakt:
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Afsluttet
        • Yale University
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Trukket tilbage
        • Emory University
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Rekruttering
        • Indiana University Riley Hospital for Children
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Linda DiMeglio, MD, MPH
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa Health Care Division of Pediatric Endocrinology
        • Kontakt:
        • Ledende efterforsker:
          • Michael Tansey, MD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Joslin Diabetes Center
        • Kontakt:
        • Ledende efterforsker:
          • Jason Gaglia, MD
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55454
        • Rekruttering
        • University of Minnesota
        • Kontakt:
        • Ledende efterforsker:
          • Antoinette Moran, MD
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64108
        • Afsluttet
        • Children's Mercy Hospital
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57104
        • Afsluttet
        • Sanford Research
    • Washington
      • Seattle, Washington, Forenede Stater, 98101
        • Rekruttering
        • Benaroya Research Institute
        • Ledende efterforsker:
          • Sandra Lord, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

8 år til 35 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.

Beskrivelse

Inclusion Criteria:

  • Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
  • Ability to sign informed consent/assent (as applicable for children).

Exclusion Criteria:

  • Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
  • Inability to comply with the study visit schedule and required assessments.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Group 1: Detectable C-peptide by MMTT

Participants with detectable C-peptide at their:

  • Last Immune Tolerance Network (ITN) T1DM week 104 study visit,
  • Last AbATE (NCT00129259) follow-up visit, or
  • Last ITN066AI T1DES visit

Detectable C-peptide is defined as a value above the lower limit of detection.

Group 2:Undetectable C-peptide by MMTT

Participants without detectable C-peptide at their:

  • Last ITN T1DM week 104 study visit,
  • Last AbATE follow-up visit, or last
  • ITN066AI T1DES visit

Undetectable C-peptide is defined as a value below the lower limit of detection.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC).

C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin.

Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL.

Baseline (Visit 0) to Month 60 (Year 5)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Insulin Use in Units per Kilogram Body Weight Per Day
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity.

Baseline (Visit 0) to Month 60 (Year 5)
Change in HbA1C
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease.

Baseline (Visit 0) to Month 60 (Year 5)
Count of Participant-Reported Major Hypoglycemic Events
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover.

Baseline (Visit 0) to Month 60 (Year 5)
Time to Undetectable C-Peptide
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates.

Baseline (Visit 0) to Month 60 (Year 5)
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

Events of interest include but are not limited to:

  • Opportunistic and serious infections
  • Malignancy
  • Cardiovascular disease
  • Development of autoimmune disease(s)
  • Hypersensitivity reactions to unrelated allergens

Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010).

Baseline (Visit 0) to Month 60 (Year 5)
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)

Events of interest include but are not limited to:

  • Opportunistic and serious infections
  • Malignancy
  • Cardiovascular disease
  • Development of autoimmune disease(s)
  • Hypersensitivity reactions to unrelated allergens

Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010).

Baseline (Visit 0) to Month 60 (Year 5)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studiestol: Linda A. DiMeglio, MD, MPH,MA, Riley Hospital for Children at Indiana University Health

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. juni 2016

Primær færdiggørelse (Anslået)

1. august 2028

Studieafslutning (Anslået)

1. august 2028

Datoer for studieregistrering

Først indsendt

6. april 2016

Først indsendt, der opfyldte QC-kriterier

6. april 2016

Først opslået (Anslået)

12. april 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.

IPD-delingstidsramme

After completion of the study.

IPD-delingsadgangskriterier

Will be available to the public.

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner